The understanding and definitions of MIS-C are evolving; the information in this article was in line with the current knowledge of Covid-19 at the time of manuscript acceptance.

Most children with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection remain asymptomatic or develop only mild symptoms. However, rare severe cases occur. During spring 2020, a new pediatric syndrome, likely a postinfectious complication of coronavirus disease 2019 (COVID-19), was described. The seminal report discussed 8 children with signs of hyperinflammation and shock and features consistent with Kawasaki disease (KD) or toxic shock syndrome. Initially named pediatric inflammatory multisystem syndrome, it is now commonly called multisystem inflammatory syndrome in children (MIS-C). Alarmingly, patients with MIS-C generally experience more severe disease than children with acute COVID-19, frequently requiring hospitalization and, at times, critical care. Cases of MIS-C have now been reported from many countries. The United States alone has had more than...

You do not currently have access to this content.